Daewoong’s Nabota Toxin Expands to Brazil in Major Export Deal
Daewoong Pharmaceutical, a major force in South Korea’s medical aesthetics industry, has announced a 180 billion korean won export agreement for its flagship botulinum toxin, Nabota. The five-year contract, signed with Brazilian partner Evolus, marks the largest international deal in the product’s history.
Nabota – marketed as Jeuveau in the United States – has been widely recognized for its high purity and reliable treatment performance. Originally approved by the U.S. FDA in 2019 nabota 100ui, it quickly became a favorite among medical professionals and experienced users alike, thanks to its predictable results, smooth injection profile, and long-lasting impact on wrinkles.
This deal gives Evolus exclusive rights to market and distribute Nabota across Brazil, one of the largest botox markets in the world. The region’s rising demand for non-surgical anti-aging solutions makes it an ideal expansion point for Daewoong’s global strategy.
For clinicians offering injectable skin treatments and toxins, Nabota presents a reliable and high-purity option that competes with top-tier global brands. For experienced DIY users who understand the importance of quality and precision, this new distribution could provide improved access to a trusted botulinum product.
Why Nabota Matters for Aesthetic Professionals and Injection Enthusiasts
Nabota stands out in the global botox landscape due to its pharmaceutical-grade refinement and consistency. Whether used to relax forehead lines, glabellar frown lines, or for other anti-aging applications, its precise effect and smooth diffusion make it a strong choice for achieving natural-looking skin rejuvenation.
Daewoong’s CEO, Jeon Seung-ho, emphasized the significance of this deal, stating, “This partnership allows us to deliver South Korea’s biotech excellence to the global stage. Our goal is to support the growing demand for advanced botulinum-based treatment options in both medical and beauty sectors.”
As the aesthetics market evolves, both professionals and trained home users are seeking toxins that combine effectiveness, safety, and affordability. Nabota’s expansion into Brazil is not only a win for Daewoong but also a step forward for the wider community of beauty practitioners looking for premium solutions to target wrinkles and other visible signs of aging—with real, lasting results.
The Editorial Team at Healthcare Business Today is made up of skilled healthcare writers and experts, led by our managing editor, Daniel Casciato, who has over 25 years of experience in healthcare writing. Since 1998, we have produced compelling and informative content for numerous publications, establishing ourselves as a trusted resource for health and wellness information. We offer readers access to fresh health, medicine, science, and technology developments and the latest in patient news, emphasizing how these developments affect our lives.
